Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | RBP dysregulation and bone marrow failure

Pedro Aguilar-Garrido • 20 Jun 2022
EHA 2022
General

Pedro Aguilar-Garrido, Spanish National Cancer Research Center (CNIO), Madrid, Spain, shares some insights into a study which investigated the impact of RNA binding protein (RBP) dysregulation on bone marrow failure and the development of hematological malignancies. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Pedro Aguilar-Garrido

1:02
RBP dysregulation and bone marrow failure: implications for future research
Pedro Aguilar-Garrido • 20 Jun 2022
3:58
RBP dysregulation and its impact on bone marrow failure and hematopoietic stem cell biology
Pedro Aguilar-Garrido • 11 Jun 2022

Related Videos

4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals